Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Read time: 1 mins
Last updated:20th Apr 2007
To determine the clinical activity of SUTENT® (sunitinib malate) in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS).
|Study start date||2007-04-20|